Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2017

View Archived Issues

Shionogi profiles key developments of second quarter of fiscal 2017

NeoMatrix Therapeutics to begin clinical testing of NMT-cP12

Enrollment begins in phase I study of Samumed's SM-04755

Integrated BioTherapeutics receives support from CARB-X to develop IBT-V02

VS-505 effective and well tolerated hyperphosphatemia treatment for hemodialysis patients

Mallinckrodt to acquire Ocera Therapeutics

Seattle Genetics submits sBLA in U.S. for Adcetris

First-in-human study reported for next-generation PET tau tracer 18F-PI-2620

FDA awards orphan drug status to RT-001 for PLA2G6-associated neurodegeneration

Hungarian Academy of Sciences identifies novel P-glycoprotein inhibitors

Janssen describes recombinant pre-fusion respiratory syncytial virus fusion proteins

Trevena submits NDA in U.S. for Olinvo

Yissum Research Development creates new methylmalonyl coenzyme A mutase fusion constructs

Mitsubishi Tanabe Pharma acquires Stelic Institute

Novel NLRP3 inflammasome inhibitors presented by IFM Therapeutics

National Institute of Biomedical Innovation patents exosome-targeted DNA vaccines

FF-1027T demonstrates tumor growth inhibition in AML xenograft model

Kamada reports topline results from study of AAT in type 1 diabetes

O-304 reduces fasting plasma glucose in phase IIa study in type 2 diabetes

Boehringer Ingelheim announces a new research collaboration and advances an existing one

IntelGenx and RedHill Biopharma resubmit NDA for Rizaport

Concentric Analgesics begins phase Ib study of capsaicin prodrug

Vedantra and Neon Therapeutics extend cancer immunotherapy research alliance

Progenics Pharmaceuticals completes rolling NDA for Azedra

GSK-3389404 well tolerated in first-in-human study

STRATOS 2 and TROPOS trials of tralokinumab in severe asthma do not meet primary endpoints

Inhibrx wins award from CARB-X for development of INBRX-111 to treat Pseudomonas infections

Oryzon Genomics cleared to conduct phase IIa SATEEN study of ORY-2001

Vedanta sublicenses IP from JSR for microbiome-derived cancer immunotherapies

Preliminary phase I results for bispecific FAP-DR5 antibody RG-7386 in solid tumor patients

Novo Nordisk offers overview of third quarter 2017

Nicox announces FDA approval of Vyzulta, recaps pipeline progress

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....